At a glance
- Originator Taisho Pharmaceutical
- Class Aniline compounds; Anti-ischaemics; Phenyl ethers; Small molecules
- Mechanism of Action Sodium-calcium exchanger inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cerebral ischaemia; Reperfusion injury
Most Recent Events
- 15 Sep 2004 No development reported - Preclinical for Cerebral ischaemia in Japan (unspecified route)
- 15 Sep 2004 No development reported - Preclinical for Reperfusion injury in Japan (unspecified route)
- 16 Apr 2003 A preclinical study has been added to the Ischemic Heart Disease pharmacodynamics section